AMEX:SLS - SLS International Stock Price, Forecast & News

Add

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

VolumeN/A

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards. Its professional team includes translators, terminologists, linguistic engineers, IT experts, technical editors and graphic designers. Read More…

Industry, Sector and Symbol

Stock Exchange AMEX

Industry N/A

Sub-IndustryN/A

SectorN/A

Current SymbolAMEX:SLS

Previous Symbol

CUSIPN/A

CIK1390478

Webhttp://www.sls-international.com/

Phone+1-417-8834549

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding SharesN/A

Market CapN/A

Next Earnings DateN/A

OptionableNot Optionable

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

SLS International (AMEX:SLS) Frequently Asked Questions

What is SLS International's stock symbol?

SLS International trades on the AMEX under the ticker symbol "SLS."

When did SLS International's stock split? How did SLS International's stock split work?

SLS International shares reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of SLS International stock prior to the reverse split would have 2 shares after the split.

How were SLS International's earnings last quarter?

SLS International Inc (AMEX:SLS) posted its earnings results on Thursday, November, 14th. The biotechnology company reported ($2.68) EPS for the quarter, missing analysts' consensus estimates of ($1.00) by $1.68. View SLS International's Earnings History.

What price target have analysts set for SLS?

2 analysts have issued 1-year price targets for SLS International's shares. Their forecasts range from $225.00 to $225.00. On average, they anticipate SLS International's stock price to reach $225.00 in the next year. View Analyst Price Targets for SLS International.

What is the consensus analysts' recommendation for SLS International?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SLS International in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SLS International.

What are Wall Street analysts saying about SLS International stock?

Here are some recent quotes from research analysts about SLS International stock:

1. According to Zacks Investment Research, "SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. " (7/23/2019)
2. Maxim Group analysts commented, "Sellas reported FYE18 with operating expenses of $31.1M which included an impairment charge of $9.6M. Net loss was ($27.7M) and loss attributable to common stockholders was ($41.3M). Sellas ended the year with $5.3M in cash. A warrant exchange in March 2019 could bring in $4.18M. The company still needs to raise capital to support the planned P3 study of galinpepimut-S (GPS) and is currently exploring strategic options, including around nelipepimut-S (NPS) in triple negative breast cancer. We believe the fundamentals remain intact and our positive views around GPS and NPS remain unchanged. That said, we are downgrading to and removing our price target while Sellas addresses its capital needs." (3/22/2019)

Has SLS International been receiving favorable news coverage?

Media headlines about SLS stock have trended somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. SLS International earned a daily sentiment score of 0.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for SLS International.

What other stocks do shareholders of SLS International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SLS International investors own include Unilife (UNISQ), Amgen (amgn), Generex Biotechnology (GNBT), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Sunesis Pharmaceuticals (SNSS), Novavax (NVAX), Athersys (ATHX), Osisko gold royalties (OR) and Fission Uranium (FCUUF).

Who are SLS International's key executives?

SLS International's management team includes the folowing people:

Angelos M. Stergiou M.D., President, Chief Executive Officer, Director
Aleksey N. Krylov, Interim Chief Financial Officer, Treasurer
Nicholas J. Sarlis M.D. Ph.D., Chief Medical Officer, Senior Vice President
Gregory M. Torre Ph.D. J.D., Chief Regulatory Officer, Senior Vice President
John Thomas Burns, Vice President - Finance, Corporate Controller
Fabio Lopez, Director
David A. Scheinberg, Director
Stephen F. Ghiglieri, Independent Director (Age 55)
Robert L. Van Nostrand, Independent Director
John Varian, Independent Director

How do I buy shares of SLS International?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SLS International's official website?

The official website for SLS International is http://www.sls-international.com/.

How can I contact SLS International?

SLS International's mailing address is 3119 S Scenic Ave, SPRINGFIELD, MO 65807-3926, United States. The biotechnology company can be reached via phone at +1-417-8834549 or via email at [email protected]

MarketBeat Community Rating for SLS International (AMEX SLS)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		419 (Vote Outperform)
Underperform Votes:		196 (Vote Underperform)
Total Votes:		615

MarketBeat's community ratings are surveys of what our community members think about SLS International and other stocks. Vote "Outperform" if you believe SLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio